Loading
Dysplasia means the cells lining the gallbladder have become abnormal but have not invaded; carcinoma in situ (stage 0) is the most abnormal form, with cancer cells still confined to the lining. Both are found by the pathologist after a gallbladder is removed and are cured by that removal when the margin is clear. Cancer Research UK notes some doctors do not regard stage 0 as a true cancer.
Gallbladder cancer develops through a metaplasia, dysplasia, carcinoma sequence in chronically inflamed mucosa (Lewis 2007; Hundal 2014). The WHO classification (5th edition, 2019; Nagtegaal 2020) names the flat precursor biliary intraepithelial neoplasia, graded low or high, with high-grade lesions equivalent to carcinoma in situ, and the mass-forming precursor the intracholecystic papillary neoplasm (Adsay 2012). In TNM 8th edition carcinoma in situ is Tis, stage 0: cancer cells confined to the lining with no invasion, rarely found except when a gallbladder is removed for other reasons (CRUK stages and grades). Early carcinomas confined to or above the muscle layer (Tis, T1a, T1b) are usually invisible to the naked eye (60 percent of 190 cases), occur about a decade younger than advanced cancers (mean 57.9 years) and have excellent outcomes: 92.3 percent five-year and 90.4 percent ten-year survival in a high-incidence series that sampled every specimen fully. The exception is extension of the intraepithelial tumour into Rokitansky-Aschoff sinuses, present in 17.8 percent, after which 39 percent died of disease against 4 percent without, often years later (Roa 2013). In primary sclerosing cholangitis dysplasia and carcinoma are common enough (37 and 14 percent of explanted gallbladders) that guidelines advise cholecystectomy for any polyp; a later cohort found most such polyps benign and proposed short-interval surveillance before surgery in the absence of high-risk features (Lewis 2007; van Erp 2020).
What differs in treatment: Tis with a clear cystic duct margin needs no operation beyond the cholecystectomy already done. A positive cystic duct margin, or high-grade dysplasia running into the cystic duct, prompts consideration of bile duct margin re-excision, and Rokitansky-Aschoff sinus involvement is a reason to consider further surgery and to follow the patient for years (Roa 2013). The pathology protocol matters: at least three sections and the cystic duct margin from every routine specimen in high-incidence settings, and complete embedding when dysplasia or cancer is found (Aloia 2015).
Almost always an incidental pathology finding. In 100 consecutive liver explants for primary sclerosing cholangitis, 37 percent of gallbladders showed dysplasia (15 high grade) and 14 percent adenocarcinoma (Lewis 2007); in the general population the frequency is far lower and not reliably measured.
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
Same organ: Glucagonoma, VIPoma, Somatostatinoma, Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma (perihilar and distal), Biliary tract cancer (all types), Neuroendocrine tumours, Pancreatic neuroendocrine tumours, Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma, Gallbladder cancer, Gallbladder adenocarcinoma, Papillary carcinoma of the gallbladder, Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Neuroendocrine carcinoma of the gallbladder, Incidental gallbladder cancer (found after cholecystectomy), Cystic duct carcinoma, Ampullary cancer (ampulla of Vater), Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic acinar cell carcinoma, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatoblastoma, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma), Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma), Solid pseudopapillary neoplasm of the pancreas
No further surgery; follow-up because occasional late recurrences reflect a field effect.
Consider bile duct margin re-excision or further surgery at a hepatobiliary centre.
Cholecystectomy advised for polyps of any size by international guidelines; a 2020 cohort supports short-interval imaging first when no high-risk feature is present.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Carcinoma in situ and dysplasia of the gallbladder" OR ABSTRACT:"Carcinoma in situ and dysplasia of the gallbladder" OR TITLE:"Biliary intraepithelial neoplasia of the gallbladder" OR ABSTRACT:"Biliary intraepithelial neoplasia of the gallbladder" OR TITLE:"BilIN" OR ABSTRACT:"BilIN" OR TITLE:"High-grade dysplasia of the gallbladder" OR ABSTRACT:"High-grade dysplasia of the gallbladder" OR TITLE:"Low-grade dysplasia of the gallbladder" OR ABSTRACT:"Low-grade dysplasia of the gallbladder" OR TITLE:"Tis gallbladder cancer" OR ABSTRACT:"Tis gallbladder cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Carcinoma in situ and dysplasia of the gallbladder, not a curated reading list.
No targets or pathways are linked to this cancer yet. Browse the gene hub →
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
Newly diagnosed? Read the first 60 days with Carcinoma in situ and dysplasia of the gallbladder, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.